NORFOLK SOUTHERN CORP
NORFOLK SOUTHERN CORP (NSC) Stock News
The latest NSC headlines and market coverage — 6 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
BioNTech and Bristol Myers Squibb announced positive Phase 2 data for pumitamig (BNT327/BMS986545), a PD-L1xVEGF-A bispecific immunomodulator, combined with docetaxel in patients with advanced NSCLC who progressed after first-line immunotherapy plus chemotherapy. The trial showed a confirmed objective response rate of 36.7%, median progression-free survival of 6.9 months, and a manageable safety profile, demonstrating potential improvement over standard-of-care docetaxel which typically delivers 3.6-3.9 months PFS.
- GlobeNewswire Inc.·
ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial
ORIC Pharmaceuticals announced promising Phase 1b data for enozertinib in first-line EGFR atypical NSCLC patients, demonstrating 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with an 88% 6-month landmark PFS. The company plans to initiate the Redwood-1 global Phase 3 registrational trial in 1H 2027, enrolling approximately 360 patients.
- GlobeNewswire Inc.·
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
Cullinan Therapeutics announced the initiation of a New Drug Application (NDA) submission to the FDA for zipalertinib in combination with platinum-based chemotherapy for treating previously untreated EGFR exon 20 insertion NSCLC. The Phase 3 REZILIENT3 trial met its primary endpoint, demonstrating statistically significant improvement in median progression-free survival. The NDA submission is expected to be completed by year-end 2026 under the FDA's Real-Time Oncology Review program.
- GlobeNewswire Inc.·
Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care
The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.
- Zacks Investment Research·
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
GSK announced positive data from the ARROS-1 study showing Jideytro (zidesamtinib) achieved a 94% response rate in first-line ROS1-positive NSCLC patients, with 90% remaining progression-free at 12 months and 70% of patients with brain metastases achieving complete tumor clearance. The drug was acquired through GSK's purchase of Nuvalent and is expected to support a supplemental FDA application for first-line use expansion.
- Zacks Investment Research·
AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal
AstraZeneca announced positive Phase III SANOVO study results showing that Tagrisso (osimertinib) combined with Orpathys (savolitinib) significantly improved progression-free survival versus Tagrisso monotherapy in treatment-naïve patients with EGFR-mutated advanced NSCLC with MET overexpression. The combination also demonstrated encouraging overall survival improvements. These results could expand the clinical utility of the combination to first-line treatment settings.